Geoffrey Lynn
Advisor & ASIT Program Scientific Lead, Chief Scientific Officer Barinthus Biotherapeutics
Seminars
Thursday 5th March 2026
Interim Clinical Results for VTP-1000, an IM-Administered ASIT Therapy for Celiac Disease
9:00 am
- SNAP-TI is an ASIT platform that enables co-delivery of multiple unique peptide antigens and rapamycin in nanoparticles of precise size and composition for local (IM or SC) administration
- VTP-1000 is a candidate for celiac disease based on SNAP-TI
- Updates on the VTP-1000 clinical program including safety and immunology parameters will be presented
